Web Stats Provided By Google Analytics

Thursday, October 13, 2016

Ocular shares rise after alliance with Regeneron

Shares of Ocular Therapeutix Inc. rose Thursday after the Bedford biotechnology company said it had struck a deal with Regeneron Pharmaceuticals Inc. to jointly develop a sustained-release treatment for wet age-related macular degeneration, a vision-threatening eye disease. Under the collaboration, Regeneron, based in Tarrytown, N.Y., has the option to exclusively license Ocular's hydrogel-based drug delivery system.

No comments:

Post a Comment

Popular Tarrytown Roundup Posts